Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517312 | 0.79 | MTNR1A (0.50) | CYP1A2CYP2A6SIGMAR1MTNR1ANQO2 | |
| SCHEMBL16398286 | 0.77 | KDM1A (0.46) | CYP1A2MTNR1AMTNR1BCYP2C19 | |
| SCHEMBL5408925 | 0.77 | KDM1A (0.46) | CYP1A2MTNR1AMTNR1BCYP2C19 | |
| SCHEMBL10889728 | 0.74 | CYP1A2 (0.46) | CYP1A2CYP2A6SIGMAR1MTNR1ANQO2 | |
| SCHEMBL7881194 | 0.73 | HTR2C (0.56) | MTNR1A | |
| SCHEMBL28078256 | 0.73 | HTR2C (0.51) | HTR2A | |
| SCHEMBL16398273 | 0.73 | HTR2C (0.51) | HTR2A | |
| SCHEMBL8690426 | 0.70 | MEN1 (0.59) | CYP1A2MTNR1ANQO2MTNR1BCYP2C19 | |
| SCHEMBL5759614 | 0.69 | MTNR1A (0.44) | CYP1A2CYP2A6SIGMAR1MTNR1A | |
| SCHEMBL5759610 | 0.69 | MTNR1A (0.44) | CYP1A2CYP2A6SIGMAR1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210122978-A1 | Liquid Crystals Comprising Cyclopentane Groups | VVI BRIGHT CHINA LTD (CN) | 2021-04-29 | — | — | US | disclosed |
| US-10745617-B2 | Liquid crystals comprising cyclopentane groups | VVI BRIGHT CHINA LTD (CN) | 2020-08-18 | — | — | US | disclosed |
| US-20180163131-A1 | LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS | VVI BRIGHT, INC. | 2018-06-14 | — | — | US | disclosed |
| US-9822303-B2 | Liquid crystals comprising cyclopentane groups | VVI BRIGHT CHINA LTD (CN) | 2017-11-21 | — | — | US | disclosed |
| US-20160237348-A1 | LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS | VVI BRIGHT, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20150034872-A1 | LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS | VVI BRIGHT, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8801966-B2 | Liquid crystals comprising cyclopentane groups | VVI BRIGHT CHINA LTD. (CN) | 2014-08-12 | — | — | US | disclosed |
| CN-101978024-B | Liquid crystals comprising cyclopentane groups | JINGMEISHENG OPTOELECTRIC MATERIAL NANJING CO LTD | 2014-05-07 | — | — | CN | disclosed |
| CN-103320141-A | Liquid crystals comprising cyclopentane groups | VVI BRIGHT INC | 2013-09-25 | — | — | CN | disclosed |
| CN-103319306-A | Liquid crystals comprising cyclopentane groups | VVI BRIGHT INC | 2013-09-25 | — | — | CN | disclosed |
| US-20110089374-A1 | Liquid Crystals Comprising Cyclopentane Groups | VVI BRIGHT, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| CN-101978024-A | Liquid crystals comprising cyclopentane groups | VVI BRIGHT INC | 2011-02-16 | — | — | CN | disclosed |
| WO-2009100204-A1 | LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS | VVI BRIGHT, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150034872-A1 | LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS | CXCR5, CCL5, ELOC | CYP1A2 581/4885CYP2A6 1692/4885SIGMAR1 3537/4885 |
| US-20210122978-A1 | Liquid Crystals Comprising Cyclopentane Groups | CXCR5, CCL5, ELOC | CYP1A2 581/4885CYP2A6 1692/4885SIGMAR1 3537/4885 |
| US-10745617-B2 | Liquid crystals comprising cyclopentane groups | CXCR5, CCL5, ELOC | CYP1A2 581/4885CYP2A6 1692/4885SIGMAR1 3537/4885 |
| US-20180163131-A1 | LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS | CXCR5, CCL5, ELOC | CYP1A2 581/4885CYP2A6 1692/4885SIGMAR1 3537/4885 |
| US-20110089374-A1 | Liquid Crystals Comprising Cyclopentane Groups | CXCR5, CCL5, ELOC | CYP1A2 581/4885CYP2A6 1692/4885SIGMAR1 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.